Expansion of an efficient drug repurposing platform for rare genetic diseases.
Award amount
$1,459,171Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Recursion Pharmaceuticals, LLC
- Proposal award date
- 2015-03-01
- Contract end date
- 2018-02-28
- UEI
- K19FFWF23DK3
- Solicitation number
- PAR14-088
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction
- Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction
- Application of an efficient drug repurposing platform to identify treatments for Cornelia De Lange Syndrome
- HLS13-04 High-Content High-Throughput Screen for Diamond Blackfan Anemia Treatments
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
5 SBIR/STTR records share this UEI (2015–2018). Reported award amounts total $3,515,236. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services